4SC, Leo Pharma Ink $125M Preclinical Deal in Psoriasis
By Cormac Sheridan
Tuesday, February 26, 2013
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales. 4SC is getting a €1 million option fee up front and would receive another €3 million should Leo, of Ballerup, Denmark, exercise its option.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.